Zanaflex, Tizanidine News

Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 9:30 a.m. ET at the New York Palace in New York, NY.

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has posted on its website briefing documents for the Peripheral and Central Nervous System Drugs Advisory Committee meeting to review Acordaa s New Drug Application for Fampridine-SR for the proposed indication of improvement of walking ability in people with ...

Acorda Therapeutics Inc., a Hawthorne-based biotech company, reported a bigger quarterly loss as it awaited regulatory action on a new multiple sclerosis drug that is designed to make walking easier for the disease's victims.

Acorda Therapeutics Inc., a Hawthorne-based biotech company, reported a bigger quarterly loss as it awaited regulatory action on a new multiple sclerosis drug that is designed to make walking easier for the disease's victims.

Previously, Ms. Khan was the Executive Director, Business Development at Acorda.

Acorda Therapeutics Inc., a Hawthorne-based biotech company, reported a bigger quarterly loss as it awaited regulatory action on a new multiple sclerosis drug that is designed to make walking easier for the disease's victims.

July 27, 2009 Acorda Therapeutics, Inc. closed at $26.35 on a volume of 323,472 shares.

Jul 28, 2009 - Acorda Therapeutics, Inc. announced today that it will report its financial results for the second quarter 2009 on Tuesday, August 4, 2009 at 8:30 a.m. ET before the U.S. financial markets open.

Jun 8, 2009 - Acorda Therapeutics, Inc. today announced that, in response to its eligibility application to the European Medicines Agency for Fampridine-SR, the EMEA has notified the Company that Fampridine-SR is eligible to be submitted for a Marketing Authorization Application via the Agency's Centralized Procedure.

Spasticity is a condition when certain muscles are continuously contracted. This contraction causes stiffness or tightness of the muscles and may interfere with movement, speech, and the way people walk.

May 6, 2009 - Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has accepted the Fampridine-SR New Drug Application for filing, assigning Priority Review and a Prescription Drug User Fee Act date of October 22, 2009.

HAWTHORNE, N.Y., Apr 29, 2009 -- --Greatest Changes in Income Level Due to Mobility Loss Occur Early On, as People with MS Transition from Normal Mobility to Minimal Mobility Impairment People with multiple sclerosis experience reduced income and earning potential as their mobility impairment increases, according to data collected from more than ...